Alnylam Pharmaceuticals Stock Price

1.68 (0.97%)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Alnylam Pharmaceuticals Inc ALNY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.68 0.97% 174.63 16:00:10
Open Price Low Price High Price Close Price Prev Close
171.82 171.82 175.76 174.63 172.95
Bid Price Ask Price Spread News
172.47 178.00 5.53 - 1
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
9,747 530,097 $ 174.02 $ 92,246,324 617,072 119.29 - 178.41
Last Trade Time Type Quantity Stock Price Currency
16:58:40 priorref 1,766 $ 174.63 USD

Alnylam Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 20.53B 117.55M 100.93M $ 492.85M $ - -7.45 -22.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -18.19k 0.30%

more financials information »

Alnylam Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALNY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week167.19177.53164.94173.05928,4097.444.45%
1 Month140.74177.53136.85159.77722,57833.8924.08%
3 Months137.30177.53125.08146.99551,50837.3327.19%
6 Months138.30178.41124.00150.07621,13336.3326.27%
1 Year153.51178.41119.29145.19571,50621.1213.76%
3 Years103.48178.4160.27107.97726,25571.1568.76%
5 Years57.11178.4131.3894.94859,449117.52205.78%

Alnylam Pharmaceuticals Description

Alnylam Pharmaceuticals Inc is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Your Recent History
Alnylam Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.